Guido Dalbagni

Memorial Sloan Kettering Cancer Center

Papers

5

Total Citations

980

H-Index

5

About

Guido Dalbagni is a leading urologic oncologist whose research has fundamentally reshaped surgical practice for bladder and kidney cancers. He is best known for his landmark contributions to the evidence base for minimally invasive surgery, particularly through his leadership of a pivotal randomized clinical trial comparing open radical cystectomy (ORC) to robot-assisted laparoscopic radical cystectomy (RARC). His 2014 paper on this trial, cited over 590 times, provided crucial early data on perioperative outcomes, while his 2018 follow-up established long-term oncologic equivalence between the two approaches. Dalbagni has also advanced the field of nephron-sparing surgery, demonstrating the viability of minimally invasive partial nephrectomy for larger renal tumors. More recently, his work has focused on patient-centered outcomes, including health-related quality of life and specific complications like uretero-enteric strictures, further refining surgical decision-making. Through these high-impact studies, Dalbagni has provided the rigorous, randomized evidence needed to validate the adoption of robotic techniques in complex urologic oncology, directly influencing treatment guidelines and improving recovery for thousands of patients worldwide.

Research Focus

Key Achievements

5
H-Index
5
Papers
980
Total Citations
196
Avg Citations/Paper
🏆 Most Cited Paper
Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial
596 citations · 2014
📈 Most Prolific Year: 2014 (1 Papers)
🤝 Key Collaborators: 31
🏛 Institutions: Memorial Sloan Kettering Cancer Center

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago